Expert Insights

Catherine Diefenbach, MD, discusses evolving first-lline treatment options for patients with classical Hodgkin lymphoma, highlighting findings from the S1826 and HD21 trials, the integration of nivolumab and AVD and brentuximab vedotin-based...

Marc Braunstein, MD, PhD, discusses advances in CAR T-cell therapy for patients with relapsed or refractory multiple myeloma, highlighting long-term treatment-free remissions, emerging BCMA-directed therapies such as anitocabtagene...

Francesco Maura, MD, discusses the evolving role of whole-genome sequencing in multiple myeloma precursor conditions, highlighting how genomic classification may distinguish malignant transformation from non-malignant disease, improve...

Olatunji Alese, MD, and Efrat Dotan, MD, discuss the emerging role of RAS inhibitors in pancreatic cancer, weighing significant efficacy advances against questions surrounding real-world patient selection, resistance, long-term outcomes,...

Stephanie Berg, DO, discusses first-line treatment selection for patients with metastatic clear cell renal cell carcinoma, highlighting the trade-offs between dual immunotherapy and immunotherapy plus tyrosine kinase inhibitor combinations,...

Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...